ストックスクリーナーアプリを入手
102.38
1.13%
1.14
アフターアワーズ：
103.83
1.45
+1.42%
前日終値:
$101.24
開ける：
$101.19
24時間の取引高:
2.56M
Relative Volume:
1.70
時価総額：
$20.45B
収益：
$5.36B
当期純損益:
$1.43B
株価収益率:
14.48
EPS:
7.0718
ネットキャッシュフロー:
$1.42B
1週間 パフォーマンス:
+5.83%
1か月 パフォーマンス:
+5.04%
6か月 パフォーマンス:
-0.14%
1年 パフォーマンス:
+52.26%
1日の値動き範囲:
$100.81
$106.37
1週間の範囲:
$92.18
$106.37
52週間の値動き範囲:
$66.74
$112.29
Incyte Corp Stock (INCY) Company Profile
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
102.38 | 20.23B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-02-05 | 開始されました | H.C. Wainwright | Buy |
| 2026-01-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability - ChartMill
Incyte’s sale of Wilmington offices generates just 10 cents in real estate taxes - Spotlight Delaware
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart.com
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
INCY insider files Form 144 to sell 2,639 shares (INCY) - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo Finance
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Zilurgisertib FOP data to debut at ENDO 2026 before Sept. 26 FDA PDUFA date - Stock Titan
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative
Incyte (NASDAQ: INCY) exec has 25,469 shares withheld to cover taxes - Stock Titan
Incyte Stock Drops as Cancer Drug Data Hits: Wall Street Split Remains in Focus - Bez Kabli
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Citizens maintains Incyte stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Stifel reiterates Incyte stock Buy rating on DLBCL data strength - Investing.com
H.C. Wainwright reiterates Incyte stock rating on lymphoma data - Investing.com
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL - BioSpace
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasit - GuruFocus
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasitamab - GuruFocus
Incyte (INCY) Monjuvi Shows Promise as First-Line Treatment for Lymphoma - GuruFocus
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate By Reuters - Investing.com
Incyte drug combo cuts risk of high-risk lymphoma worsening by 25% - Stock Titan
Incyte (INCY) accounting officer sells 2,051 common shares - Stock Titan
INCYTE (NASDAQ: INCY) director exercises 15,000 options and has shares withheld for taxes - Stock Titan
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Morgan Stanley sells INCY common shares (INCY) via Form 144 notice - Stock Titan
DIADEMA PARTNERS LP's Incyte Corp(INCY) Holding History - GuruFocus
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte to stream Goldman Sachs healthcare conference talk June 9 - Stock Titan
1INCY.MI Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (BIT:1INCY) - ChartMill
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out - Barchart.com
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup - ChartMill
Continuum Advisory, LLC's Incyte Corp(INCY) Holding History - GuruFocus
INCY Initiates Coverage On Bernstein -- Rating Set to Market Per - GuruFocus
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
3.22%
1.54%
大文字化:
|
ボリューム (24 時間):